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Background: Bipolar manic episodes often require hospital admission to ensure patient safety. The antipsychotic
quetiapine is a common treatment for bipolar mania and is available in immediate release (IR) and extended
release (XR) formulations; however, outcomes in patients receiving these different formulations have not been
directly compared in an acute hospital setting.
Methods: We conducted a multinational, observational, retrospective cohort study to describe and compare
hospital stay in patients admitted for an acute bipolar manic episode treated with quetiapine IR or XR from
1 October 2009–1 October 2010. The primary outcome measure was comparison of length of stay (LOS) using
zero-truncated negative binomial regression.
Results: In total, 1230 patients were included (659 in the IR cohort; 571 in the XR cohort). The median LOS
(interquartile range) was 18.0 days (12.0, 28.0) in the IR cohort and 20.0 days (12.0, 34.0) in the XR cohort, respectively.
LOS was not significantly associated with quetiapine formulation irrespective of whether or not clinical characteristics
were taken into account (p = 0.820 and p = 0.386, respectively). Overall, 84.2% and 84.4% of patients in the IR and XR
cohorts, respectively, had not previously used quetiapine; of these patients, 78.7% and 68.9% received one total daily
dose, and 14.4% and 23.9% received dose titration. Over half of patients received antipsychotic monotherapy (53.1%
and 58.3% in the IR and XR cohorts, respectively) and most received a daily quetiapine dose ≥ 400 mg (64.9% and
71.8%, respectively, for quetiapine monotherapy and 59.9% and 80.3%, respectively, for combination treatment).
As a secondary outcome, multivariate analysis was used to identify other factors that affect LOS. Factors associated with
a longer hospital stay included public funding versus private, maximum number of new medications administered, did
not receive lithium and did not receive anxiolytics, sedatives/hypnotics (all p < 0.0001). Factors associated with a shorter
hospital stay included presence of drug/alcohol abuse, living accompanied and having a psychiatric medical history
(all p < 0.05).
Conclusions: LOS was not found to be associated with quetiapine formulation. However, most patients received
only one total daily dose of quetiapine without dose titration, which was unexpected and contrary to current
recommendations.
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Bipolar disorder (BD) is a serious mood disorder charac-
terised by the occurrence of one or more manic, hypo-
manic, depressive or mixed episodes [1]. The disorder
has a significant negative impact on overall well-being
and social, occupational and general functioning [2]. BD
has a high global burden and is considered the fifth most
disabling disease among adults aged 15–44 years in
terms of years of life lived with a disability [3]. Patients
who have experienced a mood episode are likely to suf-
fer recurrences, with the probability of a recurrence dur-
ing the year after recovery from an episode reported as
more than 50%, increasing to more than 90% over 5 years
[4]. The consequences of recurrent illness for patients
and healthcare providers are substantial; BD is associ-
ated with an estimated annual direct healthcare cost of
£487 per person in Europe, with direct non-medical
costs of £468 and indirect costs of £6663 [5].
Manic episodes are specific to BD type I (BD-I), which
has an estimated lifetime prevalence of 0.3–1.5% in Europe
[6]. Acute bipolar manic episodes often constitute medical
emergencies requiring admission to hospital to promote
rapid recovery. Drug therapy is central to the manage-
ment of acute mania, with mood stabilisers, typical
antipsychotics and atypical antipsychotics comprising
the most common treatment options [7,8].
Quetiapine is an atypical antipsychotic that has been
shown to be effective and is licenced for the treatment
of severe and acute bipolar mania [9,10]. Two formula-
tions are available: quetiapine immediate release (IR)
and quetiapine extended release (XR). Quetiapine IR is
given twice daily and requires dose titration over 4 days
until the target therapeutic dose is achieved, whereas
quetiapine XR is given once daily and the dose titration
is over 2 days. In the treatment of acute manic episodes,
simplified dosing and a faster titration schedule may re-
sult in more rapid improvement, which might be ex-
pected to lead to a shorter duration of hospital stay.
The European study to describe HOspital stay in
patients admitted for acute bipolarManic Episodes (HOME)
was undertaken to compare the length of hospital stay (LOS)
in patients treated with quetiapine IR or quetiapine XR.
An observational study design was chosen to provide
real-world data based on current clinical practice.
Methods
Study design and population
This was a multinational, multicentre, observational, co-
hort study (NCT01239589) of patients admitted to hos-
pital for an acute bipolar manic episode treated with
quetiapine IR or quetiapine XR during a fixed retrospect-
ive period (1 October 2009 to 1 October 2010). The
patient cohorts were identified and data were collected
between November 2010 and March 2011. The study wasundertaken at 97 participating sites across 8 European
countries (Belgium, Croatia, Denmark, Finland, Germany,
Italy, Turkey and the UK).
Patients included in the analysis fulfilled the following
criteria: diagnosed with BD (International Classification of
Diseases – tenth revision); aged ≥ 18 years; admitted for
an acute bipolar manic episode during the retrospective
period; and treated with quetiapine XR or quetiapine IR at
effective doses for manic episodes during the hospitalisa-
tion period (either during acute treatment or within
48 hours of continued hospitalisation). In patients with
more than one acute manic episode during the retrospect-
ive period, the latest episode was considered as the study
episode, which must have occurred 3 months after either
response or remission of any previous manic episode.
Patients were excluded if: they had started hospitalisa-
tion before the study episode occurred for reasons other
than a manic episode; the main reason for their hospital-
isation was not BD; they were permanently hospitalised
for BD; they were admitted for acute bipolar mania epi-
sodes but finally diagnosed with another type of episode;
or they had received both quetiapine IR and XR during
the same hospitalisation period. Patients who died dur-
ing hospitalisation, those who were participating in a
clinical trial during the hospitalisation period or who
were pregnant were also excluded from analyses.
Investigators agreed a pre-set target of patient enrol-
ment per study cohort (received quetiapine IR or XR).
All identified patients who fulfilled the study inclusion
criteria during the retrospective period were listed in an
electronic web-based data capture system. If the number
of eligible patients exceeded the target number, a com-
puter program randomly selected a sample of patients to
be enrolled in the study. Data for these randomly
selected patients were collected from the hospital
clinical records and recorded in the case report forms by
the investigators during the period from 12 November
2010 to 1 March 2011.
Ethics
This study was performed in accordance with ethical
principles consistent with the Declaration of Helsinki, the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use and Good Clinical Practice. Approval was ob-
tained from the relevant Ethics Committees according to
local regulations, as detailed at the end of the manuscript.
Due to the retrospective nature of the study, there was a
likelihood of biasing the results due to a high non-
response rate; therefore informed consent was obtained
only in countries where this was a requirement. For coun-
tries where consent was required to use patient data
(Denmark, Croatia, Italy, Germany), only data for patients
with documented consent provided were included.
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The primary study objectives were to describe the hos-
pital stay in patients admitted for an acute bipolar manic
episode who were treated with either quetiapine IR or XR
and to estimate and compare the LOS in these patients.
Secondary study objectives were: to describe demo-
graphic and other patient-related factors that could be
linked to the use of quetiapine IR and XR; assessment of
factors related to LOS in both cohorts; estimation of the
difference in adjusted number of in-hospital days for
specific subgroups of patients; and estimation of differ-
ences in use of hospital resources between the two co-
horts during their hospital stay.Sample size
A sample size of 500 per group was calculated to provide
an estimated 86.4% statistical power to show meaningful
differences in LOS, provided that the mean and standard
deviation (SD) LOS were similar to those found in a previ-
ous study with similar outcome measures (mean [SD] of
8.75 [12.18] days in the quetiapine IR group compared
with 6.91 [5.70] days in the quetiapine XR group) [11].Statistical analysis
The analysis population comprised all eligible patients
enrolled into the study for whom relevant data were
available. All statistical analyses were performed using
the statistical software system SAS Version 9.2 [12]. Re-
sults were considered significant at the 5% level.
Descriptive statistics (without statistical tests) were
used to assess demographic and patient-related factors
(e.g. medical history, disease characteristics, medications
received prior to and during hospitalisation) that could
be linked to quetiapine use.
The primary outcome of LOS was defined as the date
of discharge minus the date of admission, presented as
medians with interquartile ranges. A prespecified, two-
step analysis was undertaken to determine any differ-
ences in LOS between the cohorts: 1) a generalised lin-
ear model was fitted to the data, using the number of
days as the response, and treatment and country as ex-
planatory variables; 2) zero-truncated negative binomial
regression analysis was performed. This two-step ana-
lysis was also repeated with various demographic and
clinical characteristics included as explanatory variables
(prespecified). Sensitivity analyses were then used to assess
the impact of the selected data transformation method
(using prespecified log-normal regression analysis) and
the impact of outliers (using prespecified zero-truncated
negative binomial regression analysis) on the LOS.
Propensity score methodology (Additional file 1) was
used as an additional exploratory analysis for the com-
parison of LOS between the two cohorts.For secondary outcomes, factors associated with LOS
were determined using a sequential approach. Firstly,
univariate analyses of LOS with treatment, country and
additional demographic and clinical characteristics were
performed using zero-truncated negative binomial re-
gression. Variables with a p-value < 0.2 were considered
for inclusion in the multivariate analysis. Secondly,
multivariate analysis was performed on the factors iden-
tified in the first step and other possible confounders
and/or clinically significant factors, with the LOS as the
response (Additional file 1).
Results
Baseline demographics and clinical characteristics
A total of 1587 subjects were screened for study partici-
pation (Figure 1). Of these, 1483 were enrolled into the
study (771 in the quetiapine IR cohort and 712 in the
quetiapine XR cohort). A total of 1230 patients were eli-
gible for inclusion in the analysis population (659 and
571 in the quetiapine IR and XR cohorts, respectively).
The number of patients included in the analysis population
by country was: 47 (Belgium); 75 (Croatia); 8 (Denmark);
65 (Finland); 152 (Germany); 219 (Italy); 499 (Turkey); and
165 (UK). The main reason for exclusion from the analysis
population was failure to meet study inclusion/exclusion
criteria in both cohorts.
Baseline demographics, medical history and disease
characteristics were similar in the two cohorts (Table 1).
The proportion of patients living accompanied was 78.8%
and 73.7% in the quetiapine IR and XR cohorts, respect-
ively, and a family history of mental illness was found in
28.1% and 33.1% of patients in the quetiapine IR and XR
cohorts, respectively. The severity of the manic event lead-
ing to hospitalisation was similar in the two cohorts
(severe in 64.6% of patients in the quetiapine IR cohort
and 64.5% of those in the quetiapine XR cohort).
Prior to admission (i.e. from the onset of first symp-
toms of the study episode to hospitalisation), just over a
quarter of patients received some form of medication
(27.9% of the quetiapine IR cohort and 28.2% of the
quetiapine XR cohort). The types of medications taken by
patients in both cohorts during this period were similar.
Prior to hospitalisation, 103 patients (15.6%) in the
quetiapine IR cohort were taking quetiapine IR
(1 patient [0.2%] in the quetiapine IR cohort was taking
quetiapine XR) and 87 patients (15.2%) in the XR
cohort were taking quetiapine XR (2 patients [0.4%] in
the quetiapine XR cohort were taking quetiapine IR).
Primary outcomes
LOS
The median (interquartile range) duration of hospitalisa-
tion was 18.0 (12.0, 28.0) days for the quetiapine IR co-
hort and 20.0 (12.0, 34.0) days for the quetiapine XR
Screened
N=1587
Quetiapine IR
Screened N=811
Enrolled N=771 (95.1%)
Quetiapine XR
Screened N=776
Enrolled N=712 (91.8%)
Total Excluded N=112 (13.8%)
Took both IR and XR N=1 (0.1%)
Did not take either IR or XR N=0 (0.0%)
Data not completed in full N=1 (0.1%)
Did not take quetiapine within 48 hrs N=9 (1.1%)
Manic episode within 3 months N=19 (2.3%)
Investigator criteria(*) N=82 (10.1%)
Total Excluded N=141 (18.2%)
Took both IR and XR N=0 (0.0%)
Did not take either IR or XR N=1 (0.1%)
Data not completed in full N=1 (0.1%)
Did not take quetiapine within 48 hrs N=12 (1.5%)
Manic episode within 3 months N=18 (2.3%)
Investigator criteria(*) N=109 (14.0%)
Analysis population
N=659 (81.3%)
Analysis population
N=571 (73.6%)
Figure 1 Disposition of patients. IR, immediate release; XR, extended release; (*) Due to patient not fulfilling all the inclusion/exclusion criteria.
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try alone showed no statistically significant differences in
LOS between the two cohorts (p = 0.820). This was sub-
stantiated by the sensitivity analyses of the impact of
selected data transformation method (p = 0.125) and of the
impact of outliers on the LOS (p = 0.213), which showed
no evidence of a difference between the two cohorts. The
analysis of LOS adjusted for cohort, country and clinical
characteristics also showed no evidence of a difference
between cohorts (p = 0.386). Patients in the UK had the
longest median LOS compared with any other country
(48.0 days compared with 26.0 for Germany, 23.0 for
Belgium, 17.0 for Denmark, 22.0 for Croatia, 21.0 for
Finland, 18.0 for Turkey and 11.0 days for Italy) (Figure 2).
Estimated LOS analysed by propensity score
Using logistic regression, propensity groups were derived
based on the predicted probability of cohort member-
ship. Factors related to prescription of quetiapine XR
were: type of hospital, size of hospital, prescription of
quetiapine from first symptoms of the study episode,
and the time since diagnosis. There was no difference in
LOS adjusted for the propensity score either as a con-
tinuous covariate (p = 0.439) or as a categorical fixed
effect (p = 0.115). Furthermore, there was no difference
in LOS between cohorts in matching analysis (254
matched pairs of patients) (p = 0.752).
Description of hospital stay
The majority of patients were enrolled in regional/
national hospitals (61.2% compared with 22.7% ingeneral/district hospitals, 12.0% in rural/local/commu-
nity hospitals and 4.1% from other types of hospital).
More patients received quetiapine XR compared with
quetiapine IR at rural/local/community hospitals (17.2%
vs 7.4%), while the percentage of patients who received
quetiapine IR and quetiapine XR at general/district
(24.1% and 21.0%, respectively) and regional/national
hospitals (65.1% and 56.7%, respectively) was similar.
The majority of patients were enrolled from publically
funded hospitals (92.1%), which corresponded to 91.5%
of patients in the quetiapine IR cohort and 92.8% of
patients in the quetiapine XR cohort.
As shown in Table 2, the majority of patients were ad-
mitted to psychiatric wards (82.4%). The percentage of
patients admitted to psychiatric wards was similar in the
two cohorts (82.5% in the quetiapine IR cohort and
82.1% in the quetiapine XR cohort). The mean ± SD
number of different ward types in which patients stayed
while hospitalised was similar between the two cohorts
(1.2 ± 0.56 in the quetiapine IR cohort and 1.3 ± 0.59 in
the quetiapine XR cohort).
Data on new medication prescriptions during hospital-
isation were collected to assess any treatment differences
between the cohorts (summaries of new medications did
not include those prescribed before hospital admission).
In total, 97.0% of patients received medication during hos-
pitalisation. Antipsychotics (including quetiapine) were
the most commonly newly prescribed medication (94.9%
of patients, [quetiapine IR cohort, 95.0%; quetiapine XR
cohort, 94.7%]; some patients were already receiving
quetiapine at the time of admission), followed by
Table 1 Baseline demographics and disease characteristics
Quetiapine IR Quetiapine XR Total
Characteristic (N = 659) (N = 571) (N = 1230)
Gender (male), N (%) 337 (51.1) 279 (48.9) 616 (50.1)
Age (years), mean (SD) 42.8 (13.7) 42.4 (13.3) 42.7 (13.5)
Years in education, mean (SD) 9.9 (3.9) 10.3 (3.9) 10.1 (3.9)
Currently employed, N (%) 178 (27.0) 164 (28.7) 342 (27.8)
Cohabitation (lives accompanied), N (%) 519 (78.8) 421 (73.7) 940 (76.4)
Alcohol abuse/dependence,* N (%) 113 (17.1) 104 (18.2) 217 (17.6)
Drug abuse/dependence,* N (%) 46 (7.0) 44 (7.7) 90 (7.3)
Any relevant psychiatric medical history, N (%) 75 (11.4) 53 (9.3) 128 (10.4)
Any relevant non-psychiatric medical history, N (%) 158 (24.0) 134 (23.5) 292 (23.7)
Family history of mental illness, N (%) 190 (28.8) 189 (33.1) 379 (30.8)
Time since first diagnosis to hospital admission (years), median 5.7 6.3 5.9
Episode polarity diagnosis, N (%)
Manic 453 (68.7) 352 (61.6) 805 (64.5)
Hypomanic 18 (2.7) 25 (4.4) 43 (3.5)
Depressive 86 (13.1) 63 (11.0) 149 (12.1)
Mixed 36 (5.5) 25 (4.4) 61 (5.0)
No other specified 5 (0.8) 5 (0.9) 10 (0.8)
Unknown 61 (9.3) 98 (17.2) 159 (12.9)
Previous hospital admission due to bipolar disorder, N (%) 183 (27.8) 160 (28.0) 343 (27.9)
Any suicide attempt since diagnosis, N (%) 85 (12.9) 74 (13.0) 159 (12.9)
Severity of index manic event, N (%)
Mild 22 (3.3) 17 (3.0) 39 (3.2)
Moderate 185 (28.1) 155 (27.1) 340 (27.6)
Severe, without psychotic symptoms 178 (27.0) 166 (29.1) 344 (28.0)
Severe, with psychotic symptoms 248 (37.6) 202 (35.4) 450 (36.6)
Unavailable 26 (3.9) 31 (5.4) 57 (4.6)
IR, immediate release; XR, extended release; SD, standard deviation.
*At time of hospitalisation.
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45.8%; quetiapine XR cohort, 54.8%]), anxiolytics, seda-
tives and hypnotics (35.7% of total [quetiapine IR cohort,
32.5%; quetiapine XR cohort, 39.4%]) and lithium (25.3%
of total [quetiapine IR cohort, 27.2%; quetiapine XR co-
hort, 23.1%]). A minority of patients were prescribed anti-
depressants (5.0% of total [quetiapine IR cohort, 4.7%;
quetiapine XR cohort, 5.4%]), antiparkinsonians (4.5% of
total [quetiapine IR cohort, 3.9%; quetiapine XR cohort,
5.1%]) and other medications (4.1% of total [quetiapine IR
cohort, 3.9%; quetiapine XR cohort, 4.4%]).
Overall, 84.2% and 84.4% of patients in the IR and
XR cohorts, respectively, had not previously used
quetiapine. Of these patients that were receiving
quetiapine for the first time, most received only one
total daily dose of quetiapine (quetiapine IR cohort:
78.7%; quetiapine XR cohort: 68.9%), and only 14.4%
and 23.9% of patients, respectively, received therecommended dose titration during the first 7 days of
hospitalisation. The first in-hospital quetiapine mean
dosage was 447.7 mg for the quetiapine IR cohort and
482.4 mg for the quetiapine XR cohort. The last
in-hospital quetiapine mean dosage was 504.7 mg for
the quetiapine IR cohort and 561.4 mg for the
quetiapine XR cohort. The mean change in quetiapine
dosage (first to last) was 57.0 mg for the quetiapine IR
cohort and 78.9 mg for the quetiapine XR cohort.
Quetiapine was given as antipsychotic monotherapy in
53.1% of patients in IR cohort and 58.3% of patients in
the XR cohort. The majority of patients received a daily
dose of quetiapine ≥400 mg (patients receiving
quetiapine alone: 64.9% in the quetiapine IR cohort and
71.8% in the quetiapine XR cohort, respectively;
patients receiving quetiapine in combination with other
antipsychotics: 59.9% in the quetiapine IR cohort and
80.3% in the quetiapine XR cohort, respectively).
Quetiapine IR
Quetiapine XR
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Figure 2 Length of hospital stay (LOS). IR, immediate release; XR, extended release.
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Factors related to LOS
Multivariate analysis identified several clinical factors
related to the total LOS (Table 3). Variables associated
with a longer hospital stay were: public hospital fund-
ing, hospital admission related to BD in the previousTable 2 Description of hospital stay
Qu
Characteristic (N =
Department of admission, N (%)
Emergency room 84
Intensive care unit 11
General ward 19
Psychiatric ward 544
Other 1 (0
Time from symptom onset to admission (days), median 8.0
No. of nights in ward, median
Emergency room 1.0
Intensive care unit 5.5
General ward 13.0
Psychiatric ward 18.0
Other 5.0
Discharge status, N (%)
Discharged to home 629
Transferred to another facility 19
Other 9 (1
Unknown 2 (0
IR, immediate release; XR, extended release.12 months, not experiencing a manic episode in the
previous 12 months, a severe versus a mild manic epi-
sode, admission from a psychiatric ward versus emer-
gency room, maximum number of new medications
administered, not being treated with lithium during the
hospital stay, and not being treated with anxiolytics/etiapine IR Quetiapine XR Total
659) (N = 571) (N = 1230)
(12.7) 52 ((9.1) 136 (11.1)
(1.7) 27 (4.7) 38 (3.1)
(2.9) 21 (3.7) 40 (3.3)
(82.5) 469 (82.1) 1013 (82.4)
.2) 2 (0.4) 3 (0.2)
8.0 8.0
1.0 1.0
18.0 14.0
20.5 15.0
19.0 18.0
10.5 9.0
(95.4) 531 (93.2) 1160 (94.4)
(2.9) 27 (4.7) 46 (3.7)
.4) 10 (1.8) 19 (1.5)
.3) 2 (0.4) 4 (0.3)
Table 3 Factors associated with the total length of hospital stay (LOS)
Estimate (95% CI) t-statistic p-value
Site characteristics
Public funding vs private 1.442 (1.259, 1.651) 5.28 < 0.0001
Less than 50 beds vs more than 600 beds 1.015 (0.851, 1.212) 0.17 0.8651
50 to 200 beds vs more than 600 beds 0.936 (0.846, 1.035) −1.29 0.1966
201 to 600 beds vs more than 600 beds 1.011 (0.923, 1.107) 0.24 0.8101
Patient demographics
Lives accompanied vs alone 0.889 (0.812, 0.974) −2.54 0.0112
Any present alcohol/drug abuse or dependence 0.883 (0.805, 0.968) −2.66 0.0079
Medical history
Any psychiatric medical history 0.868 (0.770, 0.978) −2.33 0.0202
Any non-psychiatric medical history 1.064 (0.980, 1.156) 1.48 0.1392
Any BD hospital admission in prior 12 months 1.179 (1.071, 1.297) 3.37 0.0008
No manic event in prior 12 months 1.188 (1.076, 1.312) 3.41 0.0007
Severity of manic event
Moderate vs mild 0.931 (0.763, 1.136) −0.71 0.4799
Severe vs mild 1.250 (1.031, 1.514) 2.27 0.0231
Department of admission
ICU vs ER 0.991(0.782, 1.255) −0.08 0.9397
General ward vs ER 1.236 (0.985, 1.551) 1.84 0.0667
Psychiatric ward vs ER 1.180 (1.035, 1.345) 2.47 0.0137
Treatment
Maximum no. of new medications administered 1.154 (1.122, 1.187) 10.00 < 0.0001
0.969 (0.903, 1.040) −0.87 0.3861
Did not receive lithium 1.211(1.107, 1.325) 4.18 < 0.0001
Did not receive anxiolytics, sedatives/hypnotics 1.222 (1.119, 1.334) 4.47 < 0.0001
Received antidepressants 1.144 (0.971, 1.348) 1.61 0.1069
% quetiapine use 0.999 (0.996, 1.001) −1.29 0.1970
BD, bipolar disorder; CI, confidence interval; ER, emergency room; ICU, intensive care unit.
Factors associated with a LOS are shown in bold. Estimates with 95% CI were calculated by zero-truncated negative binomial regression multivariable analysis.
Only clinical factors included in the final model are shown. Countries were included in the model but are not shown. Clinical factors with a p-value of < 0.05 were
considered significant.
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associated with a shorter LOS were: living accompanied,
presence of alcohol/drug abuse/dependence and having a
psychiatric medical history.
Comparison of LOS in patient subgroups
Analysis of several pre-specified subgroups, adjusted for co-
hort and country, was performed to assess any association
with the type of quetiapine received. The analyses suggested
that none of the variables assessed were associated with the
type of quetiapine received during hospitalisation (as deter-
mined by zero-truncated negative binomial regression).
Use of resources during hospitalisation
Service visits during the hospital stay included psycholo-
gists, group therapy, substance abuse counselling andsocial worker visits. Overall, there were no differences
(as determined by logistic regression) in the incidence of
resource use between the quetiapine IR and XR cohorts
when all service visits were taken into account (odds
ratio [OR] = 1.30, 95% confidence interval [CI]: 0.87,
1.94; p = 0.201). Similarly, there were no differences (as
determined by logistic regression) between the cohorts in the
incidence of laboratory tests (OR= 0.93, 95% CI: 0.34, 2.57;
p = 0.890). Laboratory tests received during hospitalisation
included blood/biochemistry tests, and echocardiograms.
Discussion
The length of hospital admission is often used as a direct
indicator of effectiveness of treatments for psychiatric
disorders including BD. Over the past several decades,
the LOS for patients requiring psychiatric hospitalisation
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economic pressures but by advances in clinical practice
with a focus on treatment in outpatient settings [13-15].
There is some debate as to the optimum LOS in psychi-
atric patients; some studies argue that patients with
depression who are discharged after a brief inpatient
treatment are more depressed and more globally im-
paired on discharge [13], while other studies suggest that
shorter stay is as effective or more effective than long-
term inpatient programmes among depressed patients
[16,17], or patients with severe mental illness [18].
This retrospective study was undertaken to describe
and compare hospital stay in patients admitted for an
acute bipolar manic episode treated with either
quetiapine IR or quetiapine XR. The study was designed
to obtain information on actual clinical practice and to
better understand the unmet medical and health care
needs in patients admitted to hospital with bipolar
mania. We aimed to minimise selection bias through use
of a retrospective design to avoid prescription induction
and additional procedures, a random sampling process
for study patient selection, and enrolment of a similar
number of patients in each cohort.
In our study, the LOS was not found to be significantly
associated with the quetiapine formulation received, irre-
spective of whether or not intervening factors were
taken into account. There were also no differences in
LOS when propensity score methodology was applied. It
had been expected that the faster titration to therapeutic
dosages possible with quetiapine XR might lead to faster
resolution of symptoms and a shorter hospital stay in
patients treated with this formulation compared with
those who received quetiapine IR. However, the data col-
lected revealed that in this population of acutely manic
hospitalised patients, most were treated with only one
total daily dose of quetiapine. Furthermore, only a
minority of patients in both cohorts actually had a dose
titration during the first 7 days of hospitalisation, with
very little change from the first to the last in-hospital
quetiapine dosage seen in either cohort, thus were not
following the recommendation that quetiapine IR should
be given twice daily with a 4-day dose titration. As a
result, the presumed advantage of quetiapine XR is diffi-
cult to assess; this off-label use of IR may lead to different
outcomes that are not captured by LOS. A numerically
higher proportion of patients in the quetiapine XR cohort
than in the quetiapine IR cohort were receiving anti-
psychotic monotherapy, which may warrant further re-
search to explore whether quetiapine XR could be a more
cost-effective treatment. The proportion of patients on
quetiapine XR that reached a daily dose of ≥ 400 mg
was numerically slightly higher than for patients on
quetiapine IR, both as monotherapy and in combination
with other antipsychotics. Factors found to be related toprescription of quetiapine XR were type of hospital, hos-
pital size, XR prescription from first symptoms and time
since diagnosis.
As expected, the majority of patients admitted to hos-
pital for a manic bipolar episode received new prescrip-
tions; antipsychotic prescriptions alone were received by
95% of patients. Somewhat surprisingly, 5% of patients
received new prescriptions for antidepressants during
hospitalisation. This observation is not only counter-
intuitive, but also contradicts treatment guidelines which
recommend ceasing antidepressant treatment at the on-
set of manic episodes [19]. Although several studies have
investigated the role of antidepressants in the switch
from depression to mania [20,21], and antidepressant
use in bipolar mania has been recorded in other obser-
vational studies such as EMBLEM and WAVE-bd [8,22],
we know of no controlled, randomised studies investi-
gating the use of antidepressants during manic episodes.
Based on our findings, we believe more research is
needed to explore how widespread this clinical practice
is and whether it confers any benefits to patients.
In our study, the median LOS was found to be
18.0 days for the quetiapine IR cohort and 20.0 days for
the quetiapine XR cohort. This was higher than the LOS
observed in a US study [11], which collected national
data from an administrative database and was used to
calculate the study sample size (average 8.75 days in the
IR cohort and 6.91 days in the XR cohort). Similar LOS
in bipolar manic patients prescribed quetiapine IR or XR
were subsequently reported by a US study (least squares
mean 9.6 days in the IR cohort vs 9.0 days in XR cohort)
[23]. Our findings are more consistent with a European
study, which found that patients with BD (all polarities)
were hospitalised for a mean length of 18.1 days in Spain
and 20.4 days in France [24]. The authors of this study
noted that hospitalisations for patients with BD appeared
to be shorter in the US compared with Europe, although
the LOS in our study was found to differ among the
participating countries, with patients in the UK having
the longest median LOS compared with any other
country. These differences among countries may reflect
variation in clinical practice for the management of
acute bipolar mania, differences in access to participat-
ing hospitals, and cultural factors influencing health-
seeking behaviours.
LOS has been shown to be influenced by many factors
including living conditions, access to community ser-
vices and comorbidities [18,25,26]. Our study identified
several factors related to LOS, including recent disease
history (hospitalisation and experiencing a manic epi-
sode in the previous 12 months); degree of cohabitation;
drug and alcohol abuse; severity of the episode; and sev-
eral factors that may be influenced by the severity of the
episode (number and type of new medications received,
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that patients with a higher number of previous episodes
were more likely to stay longer in hospital, and sug-
gested that this is indicative of more severe illness [14].
Notably, not being treated with lithium or anxiolytics,
sedatives and hypnotics during hospitalisation was asso-
ciated with a longer hospital stay, which may suggest
that these treatments could improve outcomes related to
LOS in hospitalised manic patients. Inverse associations
(lithium treatment related to a shorter LOS, and anxio-
lytic/sedative/hypnotic treatment related to shorter LOS)
were not found. However, it should be noted that the
duration of lithium use could be an influencing factor
on LOS as, if treatment is started prior to (rather than
during) hospitalisation, a more pronounced effect on the
duration of hospitalisation may be seen. Another sur-
prising finding was that alcohol/drug abuse at the time
of hospitalisation was related to a shorter LOS. Alcohol
abuse during hospitalisation may be due to self-medication
as many patients discover the central nervous system de-
pressant effects of alcohol and thus use it to decrease their
anxiety and as an aid to induce sleep. Other studies
assessing the effect of this factor on hospital stay are scarce
and provide conflicting results; a retrospective study by
Fan et al. found no significant difference in LOS between
alcoholic and non-alcohol manic patients [27]. Alcohol
withdrawal in hospital is a common cause of relapse, but
also a cause of additional symptoms difficult to distinguish
from mania (agitation, euphoria) that may lead to
decreased LOS compared with a more pure acute manic
episode. Further investigation is needed to establish the
reason behind this result.Limitations
Data dispersion in LOS observed in this study was
higher than expected according to the sample size esti-
mation based on the Järbrink study [11], which may at
least in part explain why statistically significant differ-
ences were not achieved. Limitations of the retrospective
study design include the fact that the data were not ori-
ginally collected according to a defined protocol, the
potential for missing data, lack of documentation of dis-
ease severity and clinical outcomes using recognised
clinical scales, and variability between different study
sites. As this study utilised an observational design
rather than a prospective randomised design, any
probability values should be viewed with caution.
From a broader perspective of BD, it is important to
note that this study only considered the treatment of
acute manic episodes. However, morbidity from mania is
not limited to acute episodes as full recovery of func-
tioning often lags months behind remission of symptoms
[28]. Maintenance of euthymia is an important goal inthe clinical management of patients with BD and is best
achieved through long-term drug therapy [29].
Conclusions
In summary, this study was successful in describing the
hospital stay and allowing comparisons in the manage-
ment of patients admitted for an acute bipolar
manic episode treated with either quetiapine IR or
quetiapine XR. LOS was not found to be associated with
the formulation of quetiapine received. However, most
patients received only one total daily dose of quetiapine,
without dose titration at initiation of treatment, which was
unexpected and contrary to current recommendations.
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